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Abstract
Background and Purpose—Statin pretreatment has been associated with improved outcomes
in patients with ischemic stroke. Although several mechanisms have been examined in animal
models, few have been examined in patients. We hypothesized that patients using statins before
stroke onset may have greater reperfusion than patients not using statins.
Methods—Acute ischemic stroke patients underwent two MR scans: within 4.5 (tp1) and at 6
hours (tp2) after stroke onset. Regions of reperfusion were defined by prolonged MTT at tp1
which normalized at tp2. Four MTT thresholds were assessed to ensure that results were not
spuriously based on an arbitrary threshold. Baseline characteristics, relative reperfusion, and
change in NIH Stroke Scale between tp1 and 1-month follow-up (ΔNIHSS) were compared
between patients who were taking statins at stroke onset and those who were not.
Results—Thirty-one stroke patients were prospectively enrolled; 12 were taking statins, while 19
were not. Baseline characteristics did not differ between the two groups except the statin group
had greater coronary artery disease (p=0.03). Patients using statins showed significantly greater
reperfusion compared to untreated patients across all MTT thresholds. For MTT=4 seconds,
median relative reperfusion was 50% (IQR 30%,56%) in the pre-existing statin group vs. 13%
(IQR=5%,36%) in the untreated group, p=0.014. The statin group had greater ΔNIHSS (8.8±4.0
points) compared to the untreated group (4.4±5.7 points), p=0.028.
Conclusion—Statin use prior to ischemic stroke onset was associated with greater early
reperfusion and NIHSS improvement. Further studies in larger populations are required to confirm
our preliminary findings.
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Introduction
3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins) are widely prescribed for the
prevention of vascular events. The Stroke Prevention with Aggressive Reduction of
Cholesterol Level (SPARCL) trial demonstrated that atorvastatin reduced risk of recurrent
stroke by 16% compared to placebo1. In addition to having fewer events, patients taking
atorvastatin showed a trend towards improved neurological outcomes at 90 days after their
stroke outcome event2. Several additional studies have found that patients taking statins at
the time of stroke onset had improved outcomes and lower mortality than those who were
not taking statins3–6. Moreover, withdrawal of statins in patients admitted for ischemic
stroke has been associated with worse neurological outcomes, greater early neurological
deterioration, and larger infarct sizes7.
While the neuroprotective mechanisms of statins in ischemia have not been fully elucidated,
several potential roles in both animals and humans have been studied. In rodent models,
statins have been shown to promote fibrinolysis, inhibit prothrombotic pathways, and limit
infarct size8–11. In models of ischemia-reperfusion, statins have protected multiple organ
systems against reperfusion injury12, 13 and have augmented cerebral blood flow (CBF)
secondary to upregulation of endothelial nitric oxide synthase (eNOS)14, although such a
CBF effect was not reproduced in humans with atherosclerotic carotid occlusion15. In other
clinical studies, statin use was associated with greater recanalization in a cohort of ischemic
stroke patients undergoing acute intervention16, and in aneurysmal subarachnoid
hemorrhage, patients treated with statins were less likely to develop vasospasm17. In several
studies, the neuroprotective effects have been independent of cholesterol lowering10, 11.
Given the potential vascular effects of statins in the setting of ischemia, we hypothesized
that improved neurological outcomes observed with statin pretreatment may be related to
greater reperfusion during the hyper-acute phase of ischemic stroke. Thus, we measured
early reperfusion (within 6 hours of stroke onset) in acute ischemic stroke patients,
comparing patients with pre-existing statin use to untreated patients.
Methods
Patients and Inclusion Criteria
This was a retrospective analysis of data from a prospectively collected observational study
of serial MRI’s performed in acute ischemic stroke patients at a large urban tertiary care
referral center, admitting over 800 ischemic strokes per year. Data from the first 31 patients
in this study (with planned enrollment of 75 patients) were used for a retrospective analysis
of the effect of statins on reperfusion. After Institutional Review Board approval, the study
enrolled consecutive patients within 4.5 hours of stroke onset based on the following pre-
specified inclusion criteria: clinically-suspected acute cortical ischemic stroke; age ≥ 18
years; NIHSS ≥ 5; and patient or patient’s next of kin capable of informed consent.
Exclusion criteria included bilateral strokes or any acute endovascular or surgical
intervention. Both tPA-treated and untreated patients were included. For patients receiving
tPA, the study imposed no delay in time-to-tPA-treatment and no deviation from standard
practices. The NIHSS was collected prospectively by a stroke neurologist on admission, at
both imaging time points, and at one month follow-up. Clinical data including demographic
data, past medical history, and home medications were obtained by the research coordinator
prospectively during enrollment.
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Magnetic Resonance Imaging Protocol
Patients were scanned with MRI within 4.5 hours (tp1) and at 6 hours (tp2) after stroke
onset, on a 3T Siemens whole body Trio system with a circular polarized head coil. For
patients receiving tPA, the tp1 scan was performed as soon as possible after tPA bolus. The
protocol included diffusion-weighted images, FLAIR images [TR/TE=10000/115 ms;
inversion time = 2500 ms; matrix=512×416; 20 slices, slice thickness (TH)=5mm], and
dynamic susceptibility contrast (DSC) perfusion images with Gadolinium contrast injected
at 5 ml/s with a power injector (a T2*-weighted gradient echo EPI sequence; TR/
TE=1500/43 ms; 14 slices, TH=5mm, zero interslice gap; matrix=128×128). Magnetic
resonance angiography (MRA) was not performed.
Data analysis
Mean transit time [MTT=cerebral blood volume (CBV)/CBF18] was chosen to define the
perfusion deficit because MTT is uniform across gray and white matter (unlike CBF or
CBV), allowing for use of a single threshold across both tissue types19, 20. Voxels within the
middle cerebral artery (MCA) territory of the contralateral hemisphere were manually
chosen to obtain an arterial input function. Six parameter rigid image registration was
performed to align all images across both scans for each patient using FSL 3.2 (FMRIB,
Oxford, UK)21. Accuracy of image registration was evaluated manually.
MTT prolongation for each voxel within the ischemic hemisphere was calculated as: [MTT
of ischemic voxel] – [median MTT of contralateral hemisphere]. A voxel was defined as
“prolonged” if MTT was ≥ a pre-defined threshold. Because the perfusion deficit volume
varies depending on the MTT threshold chosen22, 23, four MTT prolongation thresholds (3,
4, 5, and 6 seconds) were tested to determine if results were consistent across a range of
putative thresholds. Prolonged MTT volumes provided measures of perfusion deficit
volumes at tp1 and tp2. The absolute volume of reperfusion was calculated as: [prolonged
MTT volume at tp1] – [prolonged MTT volume at tp2]. Subsequently, the relative volume
of reperfusion was calculated as: [prolonged MTT at tp1 – prolonged MTT at tp2] /
[prolonged MTT at tp1] (Figure 1). The individuals performing the reperfusion calculations
were blinded to the treatment status of the patient. Isolated regions of abnormal perfusion <
1 ml were removed from the analysis to minimize inclusion of misregistered regions or
noise-induced variations.
Statistical Analysis
Pre-existing statin use and untreated groups were compared using the Wilcoxon Rank Sum
test for continuous variables except when data was Gaussian (confirmed by the
Kolmogorov-Smirnov and D'Agostino-Pearson omnibus tests), where the t-test was used.
Fisher’s Exact test compared categorical baseline characteristics between the two groups.
Alpha ≤ 0.05 was required for statistical significance. Statistical analyses were performed
using STATA 10.1.
Statins and Relative Reperfusion
Relative reperfusion for each MTT threshold (3, 4, 5, and 6 seconds) was compared between
the untreated and statin groups. In addition to the total group, the tPA-treated subgroup was
analyzed to ensure that statin effects were not confounded by the higher proportion of statin
patients receiving tPA. A linear regression model was developed as a prediction model for
relative reperfusion based on the MTT=4 second threshold (as this is a commonly used
threshold of ischemia in acute stroke literature). Predictors were selected with a forward
stepwise procedure in which a p-value ≤ .20 was required for entry and p-value ≤ .05 was
required to be retained in the model. At each step, regression diagnostics evaluated
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distributional assumptions of the residuals and functional form of the covariates. Ten
potential covariates were considered: pre-existing statin use, tPA treatment, volume of tp1
perfusion deficit (MTT=4sec), age, gender, admission NIHSS, admission mean arterial
pressure (MAP), admission glucose, LDL, and time between tp1 and tp2 scans. Diffusion
weighted imaging (DWI) volume at tp1 was considered for inclusion in the model, however,
DWI volume demonstrated strong covariance (r=0.74, p<0.0001) with volume of tp1
perfusion deficit, leading to multi-collinearity. Therefore, we chose to include only volume
of tp1 perfusion deficit in the model to control for baseline volume of initial ischemia.
Model goodness-of-fit was assessed by Akaike's information criterion. Potential interactions
between statin use and tPA treatment or MAP were assessed.
Statins and Neurological Improvement
Neurological improvement, as assessed by ΔNIHSS (NIHSS on admission - NIHSS at 1
month), was compared in the untreated and pre-existing statin use groups. This comparison
was performed in all patients and in the tPA-treated subgroup. In the same way as described
for relative reperfusion, a forward stepwise procedure for a linear regression model was
created to identify which, of 10, baseline clinical variables predicted neurological
improvement as measured by ΔNIHSS. Potential interactions between statin use and tPA
treatment or age were assessed.
Results
Of 31 acute ischemic stroke patients enrolled, 12 were taking statins at stroke onset, while
19 were not. Patient demographics and baseline characteristics were not significantly
different between the two groups except that the statin group had significantly more patients
with a history of coronary artery disease (CAD) (p=0.03) (Table 1). Patients were imaged
with MRI at 3.0±0.8 hours (tp1) and 6.4±0.4 hours (tp2) after onset. The co-registered
images were well-aligned with the template images, yielding inaccuracies < three voxels in
any direction. In order to assess whether the location of perfusion deficit territories were
balanced between the untreated and pre-existing statin use groups, perfusion deficit
territories based on tp1 MTT maps were assigned to one of four groups: 1) internal carotid
artery (ICA), (2) complete MCA, (3) partial MCA, and (4) small MCA (Figure 2). There
were no significant differences between the two groups.
To assess how representative our study population (N=31) was relative to our hospital stroke
population (N=2057) over the 2.5 year enrollment time period, we compared characteristics
of both groups. While age, gender, and race were similar, the mean NIHSS score was higher
in the study cohort for non-tPA-treated patients. In addition, for tPA-treated patients, the
mean door-to-needle time in the study cohort was shorter compared to the hospital tPA-
treated patients (51 vs. 60 min, p=0.04). There was no difference is rate of symptomatic
intracerebral hemorrhage (Online Supplementary Data).
Statin Use is Associated with Increased Relative Reperfusion
We compared relative reperfusion in the untreated group and statin group for each of four
MTT thresholds to determine if findings were consistent across all MTT thresholds. Relative
reperfusion was greater in the statin group compared with the non-statin group for all MTT
thresholds (Figure 3a). Median reperfusion across the four MTT thresholds for the statin
group was 48% (IQR 28%, 64%) and for the untreated group was 13% (IQR 4%, 35%).
Because tPA treatment was more common in the statin group, we performed the same
analysis as above in the subset of 23 patients treated with tPA to determine if the statin
effect persisted in this subgroup. We continued to observe greater relative reperfusion in the
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statin group in three of the four MTT thresholds, with a strong trend for MTT=3 seconds
(Figure 3b). For tPA-treated patients, median reperfusion across the four MTT thresholds for
the statin group was 48% (IQR 26%, 56%) and for the untreated group, was 15% (IQR 2%,
30%).
A forward selection stepwise procedure determined which clinical variables best predicted
early reperfusion after stroke. In addition to statin use, nine baseline variables which were
hypothesized to possibly affect reperfusion were included (Table 1, top nine variables).
Clinical variables which remained in the final model included: (1) statin use, β (SE)
[regression coefficient (standard error)]=17.9(7.3), p=0.021; (2) volume tp1 perfusion
deficit, β(SE) =−0.156(0.06), p=0.024; and (3) admission MAP, β(SE)=−0.318(0.15),
p=0.040. The final model explained 41.1% of the variance in relative reperfusion (Table 2).
Therefore, at stroke onset, statin use, smaller perfusion deficit, and lower blood pressure best
predicted relative reperfusion.
Statin Use Predicts NIHSS Improvement
After assessing variables associated with reperfusion, we evaluated how pre-existing statin
use may predict neurological improvement, defined by the absolute change in NIHSS from
admission to one month follow-up (ΔNIHSS). ΔNIHSS was greater in the statin group, 8.8
±4.0 (mean +/− SD) points, compared to the untreated group, 4.4±5.7 points, p=0.028
(Figure 4a). When, the tPA-treated subgroup (n=23) were evaluated in a separate analysis,
ΔNIHSS continued to be greater in patients taking statins at stroke onset, 8.9±4.2 points,
compared to those who were not 4.4±4.9 points, p=0.048 (Figure 4b).
A forward selection stepwise procedure was utilized to develop a prediction model of
ΔNIHSS. Clinical variables which remained in the final model included: (1) pre-existing
statin use, β(SE)=4.82(1.7), p=0.010 and (2) age, β(SE)= −0.163(0.06), p=0.015. In this
model, statin use and younger age were associated with NIHSS improvement, together
explaining 31.9% of the variance in ΔNIHSS (Table 2).
Discussion
Statins and Early Reperfusion
In this retrospective study of prospectively collected MRI data, patients using statins prior to
stroke onset had 2-3-fold greater early reperfusion than patients not taking statins. This
difference persisted across all MTT thresholds examined, indicating that regardless of how
the perfusion deficit was defined (conservatively or liberally), statin use was associated with
greater reperfusion. Given the increased frequency of tPA treatment in the statin group, we
analyzed this group separately and found that statin use continued to be associated with
greater relative reperfusion.
Based on vasculoprotective effects of statins, we hypothesized that early reperfusion may be
responsible, in part, for the improved clinical outcomes seen in statin pretreated populations
in large clinical trials. Regardless of statin type, animal studies have found decreased infarct
size with statin pretreatment10, 24; however, pathways underlying this neuroprotection
continue to be investigated. Potential mechanisms leading to early reperfusion fall into three
broad categories: (1) improved blood flow / vasomotor reactivity, (2) anti-thrombotic
effects, and (3) anti-inflammatory effects. Before cholesterol-lowering properties take effect,
statins exert pleiotropic effects on the vascular wall, including the upregulation of
endothelial nitric oxide synthase (eNOS), increasing nitric oxide production with resultant
increased CBF13, 14, 25. Consistent with this mechanism, statins decreased perfusion deficits
following rodent middle cerebral artery occlusion (MCAO)26 and improved cerebral
vasomotor reactivity in stroke patients undergoing SPECT imaging27. The anti-thrombotic
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effects of statins act via increasing endogenous tPA levels9 as well as by inhibiting
plasminogen activator-18. Moreover, increased nitric oxide leads to decreased platelet
activation and aggregation10. Finally, the anti-inflammatory effect of statins was
demonstrated in large clinical trials showing prevention of vascular events in patients with
concurrent lowering of C-reactive protein28, 29. By inhibition of leukocyte and cytokine
activation, statins mitigate ischemia-reperfusion injury and accordingly may prevent ‘no-
reflow’, a phenomenon in which tissue reperfusion is not restored despite vessel
recanalization30, 31.
In a linear regression model, we identified three baseline variables which explained 41% of
the variance in relative reperfusion: statin use, perfusion deficit volume at tp1, and baseline
MAP. Our data suggests that larger perfusion deficits have relatively less reperfusion, a
finding supported by a recent report in a smaller cohort of tPA-treated patients32. A smaller
initial perfusion deficit may signify less clot burden, facilitating recanalization either
spontaneously or in the presence of thrombolytics. Clinical studies demonstrated that larger
perfusion lesions, baseline stroke severity, and large-vessel occlusion predicted infarct
growth, stroke evolution, and early neurological deterioration33, 34.
Our model revealed that higher blood pressure (BP) was significantly associated with less
reperfusion. While several observational studies have associated elevated BP early after
stroke onset with increased disability, several of these studies, including the International
Stroke Trial, found a U-shaped curve in which low BP was also associated with poor
outcomes35. Moreover, this negative relationship of BP and reperfusion opposes a common
approach of stroke physicians to avoid BP lowering, especially in chronically hypertensive
patients. In our sample, three (of seven) patients did not receive tPA due to elevated BP,
suggesting the possibility of less reperfusion due to no tPA treatment; however, tPA was not
a significant predictor of reperfusion in our sample; thus, the relationship between BP and
reperfusion warrants further study.
We chose to use reperfusion determined by MTT as an outcome measure rather than
recanalization (using MRA) because reperfusion is a more sensitive and quantitative
measure than recanalization which relies on crude measures of stenosis. Studies have shown
that recanalization may occur without tissue reperfusion due to proximal clot breakdown
with distal embolization, and reperfusion may occur in the absence of recanalization likely
due to collateral flow36–38. Moreover, a recent study comparing computed topography (CT)
perfusion to CT angiography suggested that reperfusion more accurately predicted infarct
volumes than recanalization39.
Statins and Neurological Improvement
Pre-existing statin use predicted greater neurological improvement as measured by ΔNIHSS
in the entire sample as well as in tPA-treated patients. In a multivariable model, besides
statin use, lower age also predicted improved neurological status, a finding that was not
surprising since age is one of the strongest predictors of disability after stroke40, 41.
Our finding that statin pretreatment was associated with greater neurological improvement
in NIHSS may be consistent with findings from several large clinical studies which found
improved clinical outcomes in statin pretreated patients2–6. Besides vasculoprotective
effects, statins have been reported to stimulate production of anti-apoptotic protein, Bcl-2, in
neurons and human neuroblastoma cells42, 43 and prevent glutamate-induced excitotoxicity
in cortical neurons44. Statins administered within one day of stroke were found to improve
synaptogenesis, neurogenesis, and angiogenesis in a rodent MCAO model45.
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Our study has several limitations. Limited sample size may result in type II errors due to
insufficient power. Although the study was prospective, there was no randomization of
treatment, which may lead to selection bias. The treatment groups were unblinded; however,
the investigators performing the reperfusion analysis were blinded to the clinical data. We
obtained information on statin use from patients and family without independent
confirmation. Patients using statins received more tPA than the untreated patients (though
not statistically significant), so we performed the analysis in the tPA-treated subgroup to
eliminate tPA as an independent variable, and found similar results. Ideally, the study would
be repeated with a larger sample of non-tPA treated patients. We identified greater CAD in
the statin group, as might be expected since CAD is a major indication for statin use. This
imbalance may have introduced bias favoring reperfusion due to better medical care prior to
stroke onset or limiting reperfusion due to greater medical comorbidities in CAD patients.
Our study cohort included strokes of greater severity compared to the hospital stroke
patients admitted to our institution; therefore, our results cannot be directly applied to
patients with low stroke severity. Furthermore, our study did not include MRA which would
have given information about site of occlusion and degree of recanalization. However, by
evaluating the location of the tp1 perfusion deficit territories, we did not find any significant
imbalance between the two groups (Figure 2), suggesting that bias due to unequal
distribution of occlusion sites is less likely.
Conclusions
Pre-existing statin use was associated with greater reperfusion and neurological
improvement, raising the hypothesis that statin pretreatment may improve clinical outcomes
after stroke by enhancing early reperfusion. Due to the small patient sample with non-
randomized treatment, further studies are required to confirm these findings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Calculation of Relative Reperfusion
MTT maps were prepared for each time-point. For each MTT threshold, all voxels with
values > the chosen MTT threshold were defined as “prolonged”. Prolonged MTT volumes
provided a measure of the perfusion deficit volume at tp1 and tp2. Absolute and relative
reperfusion volumes were calculated as shown. Warm colors represent maximal
hypoperfusion with longer MTT and cool colors represent no hypoperfusion with short
MTT, as shown on the color bar. The orange outline delineates a perfusion deficit defined by
an MTT threshold > 4 seconds longer than the median MTT of the contralateral hemisphere.
At tp2, the perfusion deficit shrinks; thus, the white outline delineates regions of reperfusion
using this threshold (> 4 seconds).
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Figure 2. Distribution of Perfusion Deficits at tp1 (based on MTT)
In order to assess whether the location of perfusion deficit territories were balanced between
the untreated and pre-existing statin use groups, tp1 perfusion deficit territories were
assigned to one of four groups: 1) internal carotid artery (ICA), (2) complete middle cerebral
artery (MCA), (3) partial MCA, and (4) small MCA (Figure 2). There were no significant
differences between the two groups. Example of MTT maps for each of the four groups are
shown in the upper panel, labeled A, B, C, and D for ICA, complete MCA, partial MCA,
and small MCA, respectively.
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Figure 3. Statin use and relative reperfusion
(A) Entire sample, n=31: Boxplots (median, IQR) for relative reperfusion at each MTT
threshold are shown for all 31patients. For each MTT threshold, there was significantly
greater reperfusion in the statin group compared to the untreated group. (B) tPA-treated
patients only, n=23: Boxplots for relative reperfusion at each MTT threshold are shown for
tPA-treated patients only. For each MTT threshold except MTT=3 seconds, there was
significantly greater reperfusion in the statin group compared to the untreated group.
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Figure 4. Statin use and neurological improvement
(A) Entire sample, n=31: Boxplots (median, IQR) for improvement in NIHSS from
admission to 1 month follow-up (ΔNIHSS) are shown for all 31 patients. There was greater
NIHSS improvement in the statin group compared to the untreated group. (B) tPA-treated
patients only, n=23: Boxplots for ΔNIHSS are shown for tPA-treated patients only. There
was significantly greater improvement in NIHSS in the statin group.
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Table 1







Female, n (%)* 11 (58%) 3 (25%) 0.14
Age (years), median (IQR)‡ 60 (54, 72) 62 (59, 66) 0.72
Admission NIHSS, median (IQR) 16 (10, 18) 18 (13, 20) 0.60
tPA treatment, n (%)* 12 (63%) 11 (92%) 0.11
Volume tp1 perfusion deficit (ml), median (IQR) 62 (23,116) 50 (17,88) 0.73
Time between tp1 and tp2 (min), median (IQR) 215 (187, 239) 195 (159, 223) 0.19
Admission MAP (mmHg), median (IQR) 110 (94, 145) 112 (108, 116) 0.86
Admission Glucose (mg/dl), median (IQR) 128 (101, 146) 145 (121, 165) 0.26
LDL (mg/dl), median (IQR) 100 (73, 119) 72 (59, 103) 0.16
African-American, n (%)* 6 (32%) 4 (33%) 1.0
Time from tPA-bolus to tp1 (min), median (IQR) 44 (23, 54) 50 (41, 60) 0.32
Absolute Volume Reperfusion (ml), median (IQR) 6 (3, 13) 12 (7,31) 0.06
Volume DWI lesion tp1 (ml), median (IQR) 32 (7, 55) 15 (8, 30) 0.51
Onset-to-needle time (min), median (IQR) 110 (99, 121) 110 (101, 133) 0.65
History of Hypertension, n (%)* 15 (79%) 10 (83%) 1.0
History of Diabetes, n (%)* 7 (37%) 6 (50%) 0.71
History of Congestive Heart Failure, n (%)* 5 (26%) 1 (8%) 0.36
Current Tobacco Use, n (%)* 7 (37%) 5 (42%) 1.0
History of Coronary Artery Disease, n (%)* 2 (10%) 6 (50%) 0.03
History of Stroke or TIA, n (%)* 2 (10%) 4 (33%) 0.17
†
Wilcoxon Rank Sum Test unless indicated by (*).
*
Fisher’s Exact Test was used for assessing difference in frequencies between two groups.
‡
Due to small sample size, results are expressed as median and inter-quartile range (IQR).
NIHSS = NIH Stroke Scale; MAP = Mean Arterial Pressure; LDL=Low Density Lipoprotein; DWI = Diffusion Weighted Imaging; TIA =
Transient Ischemic Attack
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Table 2
Multivariable model of clinical variables predicting relative reperfusion and ΔNIHSS
Predictors of Relative Reperfusion*
Clinical Variable β (SE)† P-value‡
Pre-existing Statin Use 17.9 (7.3) 0.021
Volume Prolonged MTT at tp1 −0.156 (0.06) 0.024
Mean Arterial Pressure −0.318 (0.15) 0.040
Predictors of ΔNIHSS from Admission to One Month§
     Clinical Variable β (SE)† P-value‡
Pre-existing Statin Use 4.82 (1.7) 0.010




P < 0.05 was considered statistically significant.
*
Model including pre-existing statin use, volume of prolonged MTT at tp1, and admission mean arterial pressure explained 41.1% of the variance
in relative reperfusion.
§
Model including the pre-existing statin use and age explained 31.9% of the variance in ΔNIHSS.
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